Author

Kai Cao

Institution: The University of Texas MD Anderson Cancer Center

Observed institution: The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-5039-021X

Observed ORCID: 0000-0001-5039-021X

OpenAlex ID: A5042959899

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

2024 · David Marin, Ye Li, et al. · Nature Medicine · 523

ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies

2024 · Piyanuch Kongtim, Pongthep Vittayawacharin, et al. · Transplantation and Cellular Therapy · 41

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

2026 · Mckenzie DiLeo, Samantha Oglesby, et al. · Cancer · 2

Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

2026 · Portia Smallbone, Kai Cao, et al. · Leukemia · 1

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

2026 · Yosra M. Aljawai, Kai Cao, et al. · Bone Marrow Transplantation

Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomes

2026 · Rohtesh S. Mehta, Yosra M. Aljawai, et al. · npj Digital Medicine

Works count: 6

Citation count: 565

H-index: 2

I10-index: 2